exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274912 RNA Name: hsa-miR-524-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53711017 End Site(bp): 53711038 External Links: hsa-miR-524-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand KLHL28 chr14 44924319 45042322 - NEDD4 chr15 55826922 55993746 - NR4A2 chr2 156324437 156342348 - PKN2 chr1 88684222 88836255 + SIK2 chr11 111602449 111730855 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000095 chr1 95609446 95616975 + hsa_circ_0000284 chr11 33307958 33309057 + hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008738.7 chr19 33207129 33207639 + AC009022.1 chr16 69976297 70065948 - AC021078.1 chr5 149494314 149504670 - AC024940.6 chr12 31280422 31280895 - AC068768.1 chr12 123262060 123262402 + AC125257.1 chr17 41848518 41851447 - AC239868.1 chr1 149861271 149862504 + AL031595.3 chr22 44139365 44153626 + AL137129.1 chr14 61734138 61776260 + FGD5-AS1 chr3 14920347 14948424 - GAS5 chr1 173858559 173868882 - MCM3AP-AS1 chr21 46229196 46259390 + MIR29B2CHG chr1 207801518 207879115 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - PITPNA-AS1 chr17 1516931 1518096 + SCARNA9 chr11 93721513 93721865 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.